Influence of age and co-medication on dolutegravir glucuronidation in paediatric patients.
HIV
UGT1A1
children
dolutegravir
drug–drug interaction
glucuronidation
pharmacokinetics
Journal
British journal of clinical pharmacology
ISSN: 1365-2125
Titre abrégé: Br J Clin Pharmacol
Pays: England
ID NLM: 7503323
Informations de publication
Date de publication:
03 Sep 2024
03 Sep 2024
Historique:
revised:
31
07
2024
received:
12
06
2024
accepted:
12
08
2024
medline:
4
9
2024
pubmed:
4
9
2024
entrez:
4
9
2024
Statut:
aheadofprint
Résumé
Dolutegravir (DTG) is primarily metabolized by uridine diphosphate glucuronosyltransferases, forming the pharmacologically inactive DTG glucuronide (DTG-gluc). We described the dolutegravir metabolic ratio (DTG-MR; DTG-gluc AUC
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e16238Subventions
Organisme : European and Developing Countries Clinical Trials Partnership
ID : TRIA2015-1078
Organisme : European and Developing Countries Clinical Trials Partnership
ID : TRIA2015-1078
Organisme : ViiV Healthcare
Organisme : Medical Research Council
ID : MC_UU_00004/03
Pays : United Kingdom
Organisme : Janssen Pharmaceutica
Organisme : Gilead Sciences
Informations de copyright
© 2024 The Author(s). British Journal of Clinical Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society.
Références
UNAIDS. UNAIDS data 2021. 2022 [cited 2022 09 August 2022]. Available from: https://www.unaids.org/sites/default/files/media_asset/JC3032_AIDS_Data_book_2021_En.pdf
Turkova A, White E, Mujuru HA, et al. Dolutegravir as first‐ or second‐line treatment for HIV‐1 infection in children. N Engl J Med. 2021;385(27):2531‐2543. doi:10.1056/NEJMoa2108793
Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV. Guidelines for the use of antiretroviral agents in pediatric HIV infection. 2022 [cited 2022 09 August 2022]. Available from: https://clinicalinfo.hiv.gov/en/guidelines/pediatric-arv
World Health Organization. Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach. 2021. [2021 01/05/2023]; Available from: https://www.who.int/publications/i/item/9789240031593
Bollen PDJ, Moore CL, Mujuru HA, et al. Simplified dolutegravir dosing for children with HIV weighing 20 kg or more: pharmacokinetic and safety substudies of the multicentre, randomised ODYSSEY trial. Lancet HIV. 2020;7(8):e533‐e544. doi:10.1016/S2352‐3018(20)30189‐2
Waalewijn H, Chan MK, Bollen PDJ, et al. Dolutegravir dosing for children with HIV weighing less than 20 kg: pharmacokinetic and safety substudies nested in the open‐label, multicentre, randomised, non‐inferiority ODYSSEY trial. Lancet HIV. 2022;9(5):e341‐e352. doi:10.1016/S2352‐3018(21)00292‐7
Ruel TD, Acosta EP, Liu JP, et al. Pharmacokinetics, safety, tolerability, and antiviral activity of dolutegravir dispersible tablets in infants and children with HIV‐1 (IMPAACT P1093): results of an open‐label, phase 1‐2 trial. Lancet HIV. 2022;9(5):e332‐e340. doi:10.1016/S2352‐3018(22)00044‐3
GSK/Viiv. TIVICAY ‐ clinical pharmacology and biopharmaceutics review(s). 2012.
de Wildt SN, Kearns GL, Leeder JS, van den Anker JN. Glucuronidation in humans. Pharmacogenetic and developmental aspects. Clin Pharmacokinet. 1999;36(6):439‐452. doi:10.2165/00003088‐199936060‐00005
Dooley KE, Sayre P, Borland J, et al. Safety, tolerability, and pharmacokinetics of the HIV integrase inhibitor dolutegravir given twice daily with rifampin or once daily with rifabutin: results of a phase 1 study among healthy subjects. J Acquir Immune Defic Syndr. 2013;62(1):21‐27. doi:10.1097/QAI.0b013e318276cda9
Chen J, Raymond K. Roles of rifampicin in drug‐drug interactions: underlying molecular mechanisms involving the nuclear pregnane X receptor. Ann Clin Microbiol Antimicrob. 2006;5(1):3. doi:10.1186/1476‐0711‐5‐3
Kinvig H, Stader F, Rajoli RKR, Cottura N, Howarth A, Owen A, Marzolini C, Siccardi M. High‐dose rifampicin for the treatment of leprosy in Hiv patients taking dolutegravir. In Conference On Retroviruses And Opportunistic Infections, Boston. 2020.
Turkova A, Waalewijn H, Chan MK, et al. Dolutegravir twice‐daily dosing in children with HIV‐associated tuberculosis: a pharmacokinetic and safety study within the open‐label, multicentre, randomised, non‐inferiority ODYSSEY trial. Lancet HIV. 2022;9(9):e627‐e637. doi:10.1016/S2352‐3018(22)00160‐6
Bevers L et al. Pharmacokinetic data of dolutegravir in second‐line treatment of children living with HIV: results from the CHAPAS4‐trial. Clin Infect Dis. 2023;77(9):1312‐1317. doi:10.1093/cid/ciad346
Bollen P, Freriksen J, Konopnicki D, et al. The effect of pregnancy on the pharmacokinetics of total and unbound dolutegravir and its main metabolite in women living with human immunodeficiency virus. Clin Infect Dis. 2020;72(1):121‐127. doi:10.1093/cid/ciaa006
Burger D, Teulen M, Eerland J, Harteveld A, Aarnoutse R, Touw D. The international interlaboratory quality control program for measurement of antiretroviral drugs in plasma: a global proficiency testing program. Ther Drug Monit. 2011;33(2):239‐243. doi:10.1097/FTD.0b013e31820fa528
Schwartz GJ, Mun[Combining Tilde]oz A, Schneider MF, et al. New equations to estimate GFR in children with CKD. J am Soc Nephrol. 2009;20(3):629‐637. doi:10.1681/ASN.2008030287
Weller S, Borland J, Chen S, et al. Pharmacokinetics of dolutegravir in HIV‐seronegative subjects with severe renal impairment. Eur J Clin Pharmacol. 2014;70(1):29‐35. doi:10.1007/s00228‐013‐1590‐9
Jacobs TG, Mumbiro V, Cassia U, et al. Twice‐daily dosing of dolutegravir in infants on rifampicin treatment: a pharmacokinetic substudy of the EMPIRICAL trial. Clin Infect Dis. 2024;78(3):702‐710. doi:10.1093/cid/ciad656
Jacobs TG, van Aerde KJ, Colbers A, Burger DM. Raltegravir‐based postnatal HIV prophylaxis therapy in a neonate after in utero dolutegravir exposure. Pediatr Infect Dis J. 2022;41(2):131‐132. doi:10.1097/INF.0000000000003364
Prueksaritanont T, Richards KM, Qiu Y, et al. Comparative effects of fibrates on drug metabolizing enzymes in human hepatocytes. Pharm Res. 2005;22(1):71‐78. doi:10.1007/s11095‐004‐9011‐5
Gilead Sciences. Vemlidy 25 mg film‐coated tablets summary of product characteristics. 2021 [cited 2023 23‐04‐2023]. Available from: https://www.ema.europa.eu/en/documents/product-information/vemlidy-epar-product-information_en.pdf
Yang G, Ge S, Singh R, et al. Glucuronidation: driving factors and their impact on glucuronide disposition. Drug Metab Rev. 2017;49(2):105‐138. doi:10.1080/03602532.2017.1293682
Spector SA, Brummel SS, Chang A, et al. Impact of genetic variants in ABCG2, NR1I2, and UGT1A1 on the pharmacokinetics of dolutegravir in children. J Acquir Immune Defic Syndr. 2024;95(3):297‐303. doi:10.1097/QAI.0000000000003358